Cancer pain

Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

Retrieved on: 
Tuesday, January 9, 2024
Pancreatic cancer, Research, Biology, Prostate cancer, Cancer, Cytokine release syndrome, CRS, AML, Population Reference Bureau, Audit committee, AMGN, NK, Neoplasm, ADC, Acute myeloid leukemia, Paracetamol, PMR, NKG2D, NSCLC, Disease, Safety, Conditional sentence, Brain, Lung cancer, Breast, PALM, Cytarabine, Senior, Prevalence, Genetics, Nonsteroidal anti-inflammatory drug, Drug discovery, Graft-versus-host disease, Ruxolitinib, TSX, Therapy, Kidney cancer, Ageing, Patient, Stomach, Complete Response Letter, Fentanyl, Breast cancer, Novartis, Society, Eli Lilly, News, Food, Cancer pain, Johnson & Johnson, Morphine, FDA, Ovarian cancer, New Drug Application, ASH, ONC, Pharmaceutical industry

Cancer is a non-treatable chronic disease that has posed a challenge to the medical fraternity for decades.

Key Points: 
  • Cancer is a non-treatable chronic disease that has posed a challenge to the medical fraternity for decades.
  • The entire medical research fraternity has prioritized cancer research in order to find new ways of treatment and analysis.
  • According to Nova one advisor, the global Oncology Cancer Drugs market was valued at USD 147.2 billion in 2021 and it is expected to hit around USD 289.2 billion by 2030 with a CAGR of 8.4% during the forecast period 2022 to 2030.
  • The article continued: “Drugs such as morphine, fentanyl, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and others are used extensively in treating cancer pain in patients with lung cancer, bone cancer, and other types of cancer.

United States Pain Management Therapeutics Market Report 2023: Neurostimulation and Online Pharmacies Surges - Forecasts to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 9, 2024
General Health, Pharmaceutical, Health, Hope, Pain management, Patient, Therapy, Research, Cancer pain, Pfizer, Nonsteroidal anti-inflammatory drug, Quality of life, Eli Lilly and Company, Medication, Arthritis, Johnson & Johnson, Pharmacy, Pain, Ageing, Pharmaceutical industry

The "United States Pain Management Therapeutics Market, Forecast 2023-2030, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Pain Management Therapeutics Market, Forecast 2023-2030, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The Pain Management Therapeutics Market in the United States demonstrates robust growth, projected to achieve a market size of US$ 33.71 Billion by 2030.
  • The report highlights a substantial investment in research and development by major pharmaceutical organizations to produce advanced pain management solutions.
  • Opioids continue to hold the largest share in the United States pain management drug market.

Marijuana Drying and Curing Equipment Market Size & Trends Analysis Report 2023-2030: Focus on U.S., Canada, Germany, Australia, Uruguay, Israel, and Colombia - ResearchAndMarkets.com

Retrieved on: 
Friday, December 8, 2023
Agriculture, Cannabis, Natural Resources, Chronic pain, Patient, Arthritis, USD, Cancer pain, Epilepsy, Cancer, Pain, Government, Drug

The "Marijuana Drying and Curing Equipment Market Size, Share & Trends Analysis Report By Country (U.S., Canada, Germany, Australia, Uruguay, Israel, Colombia), And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Marijuana Drying and Curing Equipment Market Size, Share & Trends Analysis Report By Country (U.S., Canada, Germany, Australia, Uruguay, Israel, Colombia), And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The number of weed cultivators has increased at a rapid rate with a rise in the number of countries legalizing marijuana.
  • This has had a positive impact on demand for marijuana drying and curing equipment, as consumer demand shifts to high quality and potent products.
  • This, in turn, is expected to drive demand for marijuana drying and curing equipment over the forecast period.

Global Pain Management Drugs and Devices Market Report 2023 - Rising Demand for Minimally Invasive Pain Solutions - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 30, 2023
Pharmaceutical, Health, Medical Devices, DSM-IV codes, Grünenthal, Abbott Laboratories, Johnson & Johnson, Prevalence, Etanercept, Pain, Osteoarthritis, Disease, Pain management, Patient, Rheumatoid arthritis, Cancer pain, Geography, Quality of life, Neuropathic pain, Environment, AbbVie, Device, Poultry farming, Frankincense

The "Global Market for Pain Management Drugs and Devices" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Market for Pain Management Drugs and Devices" report has been added to ResearchAndMarkets.com's offering.
  • The global market for pain management drugs and devices was valued at $80.9 billion in 2022.
  • In addition, technological advancements are serving as a critical factor in the pain management drugs and devices market.
  • Based on products, the global pain management drugs and devices market is segmented into pharmaceuticals and medical devices.

INTEGRATED PAIN SOLUTIONS WELCOMES DR. DAVID WALEGA, MD.

Retrieved on: 
Thursday, August 17, 2023
Medicine, American Board of Anesthesiology, Kowsar Publishing, Wayne State University, Neck pain, Arthralgia, Arthritis, Therapy, Cancer, Quality of life, CRPS, Pain, Knee pain, American Board of Commissioners for Foreign Missions, Cancer pain, Back pain, MD, Patient, Physician, Practitioner, Pain management, Fibromyalgia, Injury, Headache, Chronic pain, McGaw Medical Center, Northwestern University, Dentistry, Anesthesiology

Dr. Walega brings a wealth of experience and expertise to Integrated Pain Solutions.

Key Points: 
  • Dr. Walega brings a wealth of experience and expertise to Integrated Pain Solutions.
  • Additionally, he has an impressive background in treating various pain conditions, ranging from acute injuries to chronic pain syndromes.
  • Prior to joining Integrated Pain Solutions, Dr. Walega spent most of his career practicing at Northwestern University, participating in various research studies in the advancement of treating pain, specifically as it relates to non-surgical methods of treating knee pain, chronic low back pain, cancer pain and cancer survivorship related issues, and much more.
  • Integrated Pain Solutions, supported by American Pain Consortium, proudly serves Ohio with 3 clinics and 1 Ambulatory Surgical Center statewide and has been treating a wide range of acute and chronic pain conditions.

Rising Chronic Pain Diseases Propel Oxycodone Drugs Market Growth 2023 to 2028

Retrieved on: 
Monday, August 14, 2023
Osteoarthritis, Prevalence, Low back pain, Sun Pharma, Oxycodone, COVID-19, Cancer, Research, Compound annual growth rate, Cancer pain, Investment, Pain management, Fibromyalgia, Rheumatoid arthritis, Mallinckrodt, Pharmaceutical industry, Growth

The global oxycodone drugs market is expected to experience growth at a Compound Annual Growth Rate (CAGR) of 5.6% during the forecast period.

Key Points: 
  • The global oxycodone drugs market is expected to experience growth at a Compound Annual Growth Rate (CAGR) of 5.6% during the forecast period.
  • However, the use of oxycodone drugs for pain management during the pandemic increased, contributing to market growth.
  • The prevalence of chronic pain diseases, such as rheumatoid arthritis, cancer, lower back pain, and fibromyalgia, is among the major factors driving market growth.
  • The global oxycodone drugs market shows promising growth opportunities, driven by the increasing demand for pain management drugs and ongoing research and development efforts.

Grünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration

Retrieved on: 
Wednesday, August 2, 2023
Osteoporosis, Pain, Kyowa Kirin, Cancer pain, Patient, Pain management, Opioid, Pharmaceutical industry, Dentistry

Grünenthal owns a 51 percent majority share and intends to acquire the remaining share at the beginning of 2026

Key Points: 
  • Grünenthal owns a 51 percent majority share and intends to acquire the remaining share at the beginning of 2026
    AACHEN, Germany and TOKYO, Aug. 2, 2023 /PRNewswire/ -- Grünenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company and Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the successful completion of a deal to enter into a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio.
  • We are enormously grateful and proud of our colleagues who have worked tirelessly to make this Joint Venture Collaboration a reality," said Jeremy Morgan, President, Kyowa Kirin International.
  • Grünenthal owns a 51 percent majority share in the Joint Venture Collaboration, while Kyowa Kirin owns a 49 percent share.
  • Grünenthal intends to fully acquire the remaining 49 percent share via exercising an option at the beginning of 2026.

Grünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration

Retrieved on: 
Wednesday, August 2, 2023
Osteoporosis, Pain, Kyowa Kirin, Cancer pain, Patient, Pain management, Opioid, Pharmaceutical industry, Dentistry

Grünenthal owns a 51 percent majority share and intends to acquire the remaining share at the beginning of 2026

Key Points: 
  • Grünenthal owns a 51 percent majority share and intends to acquire the remaining share at the beginning of 2026
    AACHEN, Germany and TOKYO, Aug. 2, 2023 /PRNewswire/ -- Grünenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company and Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the successful completion of a deal to enter into a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio.
  • We are enormously grateful and proud of our colleagues who have worked tirelessly to make this Joint Venture Collaboration a reality," said Jeremy Morgan, President, Kyowa Kirin International.
  • Grünenthal owns a 51 percent majority share in the Joint Venture Collaboration, while Kyowa Kirin owns a 49 percent share.
  • Grünenthal intends to fully acquire the remaining 49 percent share via exercising an option at the beginning of 2026.

Rising Prevalence of Cancer-Related Pain Fuels Demand for Non-Addictive Medications: Cancer Pain Management Market Analysis 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 21, 2023
Managed Care, Pharmaceutical, Health, Oncology, Survivor, Analgesic, Therapy, Prevalence, Spinal cord, Cancer, Lung cancer, Orexo, Research, Brain, Eli Lilly, Pain, Incidence, Cancer pain, SWOT, Pain management, Patient, Pfizer, United Kingdom, Breast cancer, Disease, Porter's five forces analysis, Pharmaceutical industry, Medical imaging, Growth

The Global Cancer Pain Management Market is expected to reach over US$ 7.80 Billion by 2030, driven by the rising prevalence of cancer-related pain and the growing number of long-term cancer survivors worldwide.

Key Points: 
  • The Global Cancer Pain Management Market is expected to reach over US$ 7.80 Billion by 2030, driven by the rising prevalence of cancer-related pain and the growing number of long-term cancer survivors worldwide.
  • This growing demand for pain management medications has resulted in their widespread acceptance and consumption over other therapeutic options.
  • The Cancer Pain Management Market Report offers a detailed analysis of the industry, covering various treatment options, drug types, disease indications, and countries.
  • Additionally, the report presents epidemiological data and patient population for cancer pain, along with market share analysis and emerging therapies.

Virpax Pharmaceuticals Files Provisional Patent Application for Intranasal Delivery

Retrieved on: 
Thursday, July 13, 2023
Biotechnology, Practice Management, Health, Pharmaceutical, Oncology, Medical Devices, Research, Infectious Diseases, Hospitals, Surgery, Science, National Center for Telehealth & Technology, Patent, Central nervous system, United States Patent and Trademark Office, NCATS, Traffic barrier, Brain, National Center for Advancing Translational Sciences, CNS, Nose, Development, Cancer pain, Cooperative research and development agreement, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Post-traumatic stress disorder, Dog, Pain management, MET, Toxicology, Nanotechnology, National Institute for Health and Care Excellence, Vaccine

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has filed a new provisional patent application with the United States Patent and Trademark Office (‘USPTO’) entitled “Intranasal Delivery” related to its Envelta™product candidate.

Key Points: 
  • Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has filed a new provisional patent application with the United States Patent and Trademark Office (‘USPTO’) entitled “Intranasal Delivery” related to its Envelta™product candidate.
  • Envelta utilizes Molecular Envelope Technology (‘MET’) for the delivery of Enkephalin intranasally for severe cancer pain and non-cancer pain.
  • Nanomerics has licensed its technology to Virpax, which is utilizing the nose-to-brain MET platform to enhance drug delivery for certain of its product candidates including Envelta.
  • “We are pleased with the continued development of our patent portfolio for Envelta,” stated Anthony P. Mack , Chairman and CEO of Virpax.